Cerus Corp
Cerus Corp (CERS) Historical Volatility
CERS's 30 day historical volatility is 67.89%, in the 42nd percentile of readings over the past year. This is an average percentile, meaning Cerus Corp shares have moved roughly in line with their typical range. CERS's 30 day implied volatility sits at 140.73%, with an IV Rank of 50.40%, leaving IV 72.84 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 13, 2026.
Read more
Tracking CERS historical volatility helps you see how much Cerus Corp's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, CERS's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor CERS 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. CERS's 30 day historical volatility, or CERS HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing CERS's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced.
Historical Volatility
Historical movement is near its typical level for the past year. Neither unusually calm nor unusually active.
As of Nov 13, 2026
As of Nov 13, 2026
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →